Zymafos palifosfamide: Phase II started

Ziopharm began a 2-part, open-label, U.S. Phase II trial to evaluate Ad-RTS-IL-12 plus palifosfamide in up to 68 patients with visible lesions or

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE